Abstract
Introduction: Empirical studies on effective communication for amyloid disclosure in mild cognitive impairment (MCI) are lacking. We aimed to study the impact of six communication strategies. Method: We performed a randomized controlled trial with seven randomly assigned, video-vignette conditions: six emphasizing a communication strategy and one basic condition. All showed a scripted consultation of a neurologist disclosing positive amyloid positron emission tomography (PET) scan results to an MCI patient. Healthy individuals (N = 1017; mean age ± SD 64 ± 8, 808 (79%) female) were instructed to imagine themselves in the video, answered questionnaires assessing information recall, emotional state, and behavioral intentions, and evaluate the physician/information. Results: “Risk best practice” resulted in highest free recall compared to other strategies (P <.05), except “emotional support”. Recall in “emotional support” was better compared to “basic-‘ and elaborate information”(P <.05). “Risk best practice” resulted in the highest uncertainty (P <.001). “Teach-back” and “emotional support” contributed to the highest evaluations (P -values <.01). Conclusion: Risk communication best practices, attending to emotions, and teach-back techniques enhance information recall of amyloid-PET results, and could contribute to positive care evaluations.
Original language | English |
---|---|
Pages (from-to) | 285-295 |
Number of pages | 11 |
Journal | Alzheimer's and Dementia |
Volume | 19 |
Issue number | 1 |
Early online date | 2 Apr 2022 |
DOIs | |
Publication status | Published - Jan 2023 |
Keywords
- MCI
- amyloid status
- communication
- disclosure
- mild cognitive impairment
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Alzheimer's and Dementia, Vol. 19, No. 1, 01.2023, p. 285-295.
Research output: Contribution to journal › Article › Academic › peer-review
TY - JOUR
T1 - Identifying best practices for disclosure of amyloid imaging results: A randomized controlled trial
T2 - A randomized controlled trial
AU - Fruijtier, Agnetha D.
AU - van der Schaar, Jetske
AU - van Maurik, Ingrid S.
AU - Zwan, Marissa D.
AU - Scheltens, Philip
AU - Bouwman, Femke
AU - Pijnenburg, Yolande A. L.
AU - van Berckel, Bart N. M.
AU - Ebenau, Jarith
AU - van der Flier, Wiesje M.
AU - Smets, Ellen M. A.
AU - Visser, Leonie N. C.
N1 - Funding Information: The authors would like to thank Annelies van der Vlies, Hanneke Rhodius, and all participants and physicians for their contribution to this study. Participant recruitment was accomplished through Hersenonderzoek.nl, a Dutch online registry that facilitates participant recruitment for neuroscience studies ( www.hersenonderzoek.nl ). Hersenonderzoek.nl is funded by ZonMw‐Memorabel (project no. 73305095003), a project in the context of the Dutch Deltaplan Dementie, Gieskes‐Strijbis Foundation, the Alzheimer's Society in The Netherlands, and Brain Foundation Netherlands. The Alzheimer center Amsterdam is supported by Stichting Alzheimer Nederland and Stichting VUmc fonds. Wiesje M. van der Flier, Ellen M.A. Smets, NV, and Philip Scheltens are recipients of ABOARD, which is a public‐private partnership receiving funding from ZonMW (#73305095007) and Health∼Holland, Topsector Life Sciences & Health (PPP‐allowance; #LSHM20106). PS, Wiesje M. van der Flier, and Leonie N.C. Visser are recipients of the EU Joint Programme ‐ Neurodegenerative Disease Research (JPND) project EURO‐FINGERS (ZonMW‐Memorabel #733051102). This project is supported through the following funding organizations under the aegis of JPND ‐ www.jpnd.eu : Finland, Academy of Finland; Germany, Federal Ministry of Education and Research; Spain, National Institute of Health Carlos III; Luxemburg, National Research Fund; Hungary, National Research, Development and Innovation Office; The Netherlands, Netherlands Organisation for Health Research and Development; Sweden, Swedish Research Council. WvdF is recipient of a grant by Stichting LSH‐TKI (ABIDE‐communication: LSHM16025), a collaboration project co‐financed by Alzheimer Nederland, Piramal Neuroimaging, VU Medical Center, and Amsterdam Medical Center, and financed by the Ministry of Economic Affairs and Climate Policy by means of the PPP Allowance made available by the Top Sector Life Sciences & health to stimulate public‐private partnerships. The chair of Wiesje van der Flier is supported by the Pasman stichting. PS is recipient of JPND‐EURO‐FINGERS (ZonMW #733051102). LNCV is supported by a fellowship grant received from Alzheimer Nederland (WE.15‐2019‐05). Hersenonderzoek.nl is supported by a grant from ZonMW Memorabel (#73305095003). Funding Information: The authors would like to thank Annelies van der Vlies, Hanneke Rhodius, and all participants and physicians for their contribution to this study. Participant recruitment was accomplished through Hersenonderzoek.nl, a Dutch online registry that facilitates participant recruitment for neuroscience studies (www.hersenonderzoek.nl). Hersenonderzoek.nl is funded by ZonMw-Memorabel (project no. 73305095003), a project in the context of the Dutch Deltaplan Dementie, Gieskes-Strijbis Foundation, the Alzheimer's Society in The Netherlands, and Brain Foundation Netherlands. The Alzheimer center Amsterdam is supported by Stichting Alzheimer Nederland and Stichting VUmc fonds. Wiesje M. van der Flier, Ellen M.A. Smets, NV, and Philip Scheltens are recipients of ABOARD, which is a public-private partnership receiving funding from ZonMW (#73305095007) and Health∼Holland, Topsector Life Sciences & Health (PPP-allowance; #LSHM20106). PS, Wiesje M. van der Flier, and Leonie N.C. Visser are recipients of the EU Joint Programme - Neurodegenerative Disease Research (JPND) project EURO-FINGERS (ZonMW-Memorabel #733051102). This project is supported through the following funding organizations under the aegis of JPND - www.jpnd.eu: Finland, Academy of Finland; Germany, Federal Ministry of Education and Research; Spain, National Institute of Health Carlos III; Luxemburg, National Research Fund; Hungary, National Research, Development and Innovation Office; The Netherlands, Netherlands Organisation for Health Research and Development; Sweden, Swedish Research Council. WvdF is recipient of a grant by Stichting LSH-TKI (ABIDE-communication: LSHM16025), a collaboration project co-financed by Alzheimer Nederland, Piramal Neuroimaging, VU Medical Center, and Amsterdam Medical Center, and financed by the Ministry of Economic Affairs and Climate Policy by means of the PPP Allowance made available by the Top Sector Life Sciences & health to stimulate public-private partnerships. The chair of Wiesje van der Flier is supported by the Pasman stichting. PS is recipient of JPND-EURO-FINGERS (ZonMW #733051102). LNCV is supported by a fellowship grant received from Alzheimer Nederland (WE.15-2019-05). Hersenonderzoek.nl is supported by a grant from ZonMW Memorabel (#73305095003). Publisher Copyright: © 2022 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.
PY - 2023/1
Y1 - 2023/1
N2 - Introduction: Empirical studies on effective communication for amyloid disclosure in mild cognitive impairment (MCI) are lacking. We aimed to study the impact of six communication strategies. Method: We performed a randomized controlled trial with seven randomly assigned, video-vignette conditions: six emphasizing a communication strategy and one basic condition. All showed a scripted consultation of a neurologist disclosing positive amyloid positron emission tomography (PET) scan results to an MCI patient. Healthy individuals (N = 1017; mean age ± SD 64 ± 8, 808 (79%) female) were instructed to imagine themselves in the video, answered questionnaires assessing information recall, emotional state, and behavioral intentions, and evaluate the physician/information. Results: “Risk best practice” resulted in highest free recall compared to other strategies (P <.05), except “emotional support”. Recall in “emotional support” was better compared to “basic-‘ and elaborate information”(P <.05). “Risk best practice” resulted in the highest uncertainty (P <.001). “Teach-back” and “emotional support” contributed to the highest evaluations (P -values <.01). Conclusion: Risk communication best practices, attending to emotions, and teach-back techniques enhance information recall of amyloid-PET results, and could contribute to positive care evaluations.
AB - Introduction: Empirical studies on effective communication for amyloid disclosure in mild cognitive impairment (MCI) are lacking. We aimed to study the impact of six communication strategies. Method: We performed a randomized controlled trial with seven randomly assigned, video-vignette conditions: six emphasizing a communication strategy and one basic condition. All showed a scripted consultation of a neurologist disclosing positive amyloid positron emission tomography (PET) scan results to an MCI patient. Healthy individuals (N = 1017; mean age ± SD 64 ± 8, 808 (79%) female) were instructed to imagine themselves in the video, answered questionnaires assessing information recall, emotional state, and behavioral intentions, and evaluate the physician/information. Results: “Risk best practice” resulted in highest free recall compared to other strategies (P <.05), except “emotional support”. Recall in “emotional support” was better compared to “basic-‘ and elaborate information”(P <.05). “Risk best practice” resulted in the highest uncertainty (P <.001). “Teach-back” and “emotional support” contributed to the highest evaluations (P -values <.01). Conclusion: Risk communication best practices, attending to emotions, and teach-back techniques enhance information recall of amyloid-PET results, and could contribute to positive care evaluations.
KW - MCI
KW - amyloid status
KW - communication
KW - disclosure
KW - mild cognitive impairment
UR - http://www.scopus.com/inward/record.url?scp=85126797100&partnerID=8YFLogxK
U2 - https://doi.org/10.1002/alz.12630
DO - https://doi.org/10.1002/alz.12630
M3 - Article
C2 - 35366050
SN - 1552-5260
VL - 19
SP - 285
EP - 295
JO - Alzheimer's and Dementia
JF - Alzheimer's and Dementia
IS - 1
ER -